Comment on an open trial of lurasidone as an acute and maintenance adjunctive treatment for outpatients with treatment-resistant bipolar disorder

Journal of Clinical Psychopharmacology

Volumn 36, Issue 5, 2016, Pages 520-521

  McGrane, Ian Ross ^a   Stuhec, Matej ^b  

^a UNIVERSITY OF MONTANA   (United States)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

LURASIDONE; NEUROLEPTIC AGENT; TRANQUILIZER;

ADJUVANT THERAPY; BIPOLAR DISORDER; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; HUMAN; LETTER; MAINTENANCE THERAPY; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OUTPATIENT; PRIORITY JOURNAL; TREATMENT RESPONSE; TREATMENT OUTCOME;

ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; HUMANS; LURASIDONE HYDROCHLORIDE; OUTPATIENTS; TREATMENT OUTCOME;

EID: 84981715664     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000562     Document Type: Letter

References (6)

1. Schaffer CB, Schaffer LC, Nordahl TE, et al. An open trial of lurasidone as an acute and maintenance adjunctive treatment for outpatients with treatment-resistant bipolar disorder. J Clin Psychopharmacol. 2016;36:88-89.
2. McIntyre RS, Cucchiaro J, Pikalov A, et al. Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial. J Clin Psychiatry. 2015;76:398-405.
3. Chiu YY, Ereshefsky L, Preskorn SH, et al. Lurasidone drug-drug interaction studies: a comprehensive review. Drug Metabol Drug Interact. 2014;29:191-202.
4. Schumacher JE, Makela EH, Griffin HR. Multiple antipsychotic medication prescribing patterns. Ann Pharmacother. 2003;37:951-955.
5. Ketter TA, Sarma K, Silva R, et al. Lurasidone in bipolar I depression: a 24-week, open-label extension study. Poster presented at: US Psychiatric and Mental Health Congress; September 20-23, 2014; Orlando, FL.
6. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-Treatments meta-Analysis. Lancet. 2013;382:951-962.